Pharma major Glenmark Pharmaceuticals Ltd on Friday said it has received the final approval by the US Food and Drug Administration (USFDA) for Theophylline extended release (ER) tablets, 300 mg and 450 mg.
The company said the tablet is the bioequivalent and therapeutically equivalent to the Theophylline extended-release tablets, 300 mg and 450 mg, of Alembic Pharmaceuticals Limited.
It is used to treat wheezing, chest tightness due to asthma, lung diseases and others for easier breathing.
